Recent advances in status epilepticus

Current Opinion in Neurology

Volumn 29, Issue 2, 2016, Pages 189-198

  Trinka, Eugen ^a,b   Brigo, Francesco ^c,d   Shorvon, Simon ^e  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

^c UNIVERSITY OF VERONA   (Italy)

^d FRANZ TAPPEINER HOSPITAL   (Italy)

^e NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

antiepileptic drugs; electroencephalography; status epilepticus; treatment prognosis

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ANTICONVULSIVE AGENT; CANNABINOID; DIAZEPAM; HARKOSERIDE; LORAZEPAM; MIDAZOLAM; NEUROSTEROID; PROPOFOL; SEC BUTYLPROPYLACETAMIDE; UNCLASSIFIED DRUG; VALNOCTAMIDE; AMIDE;

DRUG EFFICACY; ELECTROENCEPHALOGRAPHY; EPILEPTIC STATE; HUMAN; PROGNOSIS; PROGNOSTIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; SEIZURES; STATUS EPILEPTICUS;

AMIDES; ANTICONVULSANTS; DIAZEPAM; HUMANS; MIDAZOLAM; SEIZURES; STATUS EPILEPTICUS;

EID: 84960408032     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000307     Document Type: Review

References (120)

1. Ong CT, Sheu SM, Tsai CF, et al. Age-Dependent sex difference of the incidence and mortality of status epilepticus: a twelve year nationwide population-based cohort study in Taiwan. PLoS One 2015; 10:e0122350.
2. Hesdorffer DC, Logroscino G, Cascino G, et al. Incidence of status epilepticus in Rochester, Minnesota 1965-1984. Neurology 1998; 50:735-741.
3. Betjemann JP, Lowenstein DH. Status epilepticus in adults. Lancet Neurol 2015; 14:615-624.
4. Rosenow F, Hamer HM, Knake S. The epidemiology of convulsive and nonconvulsive status epilepticus. Epilepsia 2007; 48 (Suppl 8):82-84.
5. KantanenAM,Reinikainen M,Parviainen I, et al. Incidence andmortality ofsuperrefractory status epilepticus in adults. Epilepsy Behav 2015; 49:131-134.
6. Shorvon S, Trinka E, guest editors. Special issue: Status Epilepticus. Epilepsy Behav 2015; 49:1-358.
7. Gastaut H. Clinical and electroencephalographical classification of epileptic seizures. Epilepsia 1969; 10 (Suppl):2-13.
8. Gastaut H. Clinical and electroencephalographical classification of epileptic seizures. Epilepsia 1970; 11:102-113.
9. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1981; 22:489-501.
10. Theodore WH, Porter RJ, Albert P, et al. The secondarily generalized tonicclonic seizure: a videotape analysis. Neurology 1994; 44:1403-1407.
11. Shinnar S, Berg AT, Moshe SL, Shinnar R. How long do new-onset seizures in children last?. Ann Neurol 2001; 49:659-664.
12. Jenssen S, Gracely EJ, Sperling MR. How long do most seizures last?. A systematic comparison of seizures recorded in the epilepsy monitoring unit. Epilepsia 2006; 47:1499-1503.
13. Dobesberger J, Ristić AJ, Walser G, et al. Duration of focal complex, secondarily generalized tonic-clonic, and primarily generalized tonic-clonic seizures: a video-EEG analysis. Epilepsy Behav 2015; 49:111-117.
14. Lowenstein DH, Bleck T, Macdonald RL. It?s time to revise the definition of status epilepticus. Epilepsia 1999; 40:120-122.
15. Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus: report of the ILAE Task Force on classification of status epilepticus. Epilepsia 2015; 56:1515-1523.
16. Naylor DE, Liu H, Wasterlain CG. Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 2005; 25:7724-7733.
17. Naylor DE, Liu H, Niquet J, Wasterlain CG. Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus. Neurobiol Dis 2013; 54:225-238.
18. Wasterlain CG, Chen JW. Mechanistic and pharmacologic aspects of status epilepticus and its treatment with new antiepileptic drugs. Epilepsia 2008; 49 (Suppl 9):63-73.
19. Rajasekaran K, Zanelli SA, Goodkin HP. Lessons from the laboratory: the pathophysiology, and consequences of status epilepticus. Semin Pediatr Neurol 2010; 17:136-143.
20. Löscher W. Single versus combinatorial therapies in status epilepticus: novel data from preclinical models. Epilepsy Behav 2015; 49:20-25.
21. Hillert MH, Imran I, Zimmermann M, et al. Dynamics of hippocampal acetylcholine release during lithium-pilocarpine-induced status epilepticus in rats. J Neurochem 2014; 131:42-52.
22. Adams B, Vaccarella L, Fahnestock M, Racine RJ. The cholinergic system modulates kindling and kindling-induced mossy fiber sprouting. Synapse 2002; 44:132-138.
23. Vezzani A, Aronica E, Mazarati A, Pittman QJ. Epilepsy and brain inflammation. Exp Neurol 2013; 244:11-21.
24. Gorter JA, van Vliet EA, Aronica E. Status epilepticus, blood-brain barrier disruption, inflammation, and epileptogenesis. Epilepsy Behav 2015; 49:13-16.
25. van Vliet EA, Otte WM, Gorter JA, et al. Longitudinal assessment of bloodbrain barrier leakage during epileptogenesis in rats. Aquantitative MRI study. Neurobiol Dis 2014; 63:74-84.
26. Bar-Klein G, Cacheaux LP, Kamintsky L, et al. Losartan prevents acquired epilepsy via TGF-b signaling suppression. Ann Neurol 2014; 75:864-875.
27. van Vliet EA, Forte G, Holtman L, et al. Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrierleakage but not microglia activation. Epilepsia 2012; 53:1254-1263.
28. Rahman S. Pathophysiology of mitochondrial disease causing epilepsy and status epilepticus. Epilepsy Behav 2015; 49:71-75.
29. Bhatnagar M, Shorvon S. Genetic mutations associated with status epilepticus. Epilepsy Behav 2015; 49:104-110.
30. Rahman S, Footitt EJ, Varadkar S, Clayton PT. Inborn errors of metabolism causing epilepsy. Dev Med Child Neurol 2013; 55:23-36.
31. Baysal-Kirac L, Tuzun E, Altindag E, et al. Are there any specific EEG findings in autoimmune epilepsies?. Clin EEG Neurosci 2015. [Epub ahead of print]
32. Pillai SC, Hacohen Y, Tantsis E, et al. Infectious and autoantibody-Associated encephalitis: clinical features and long-Term outcome. Pediatrics 2015; 135:e974-E984.
33. Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014; 13:276-286.
34. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011; 134:2802-2818.
35. Ferlisi M, Shorvon S. The outcome of therapies in refractory and superrefractory convulsive status epilepticus and recommendations for therapy. Brain 2012; 135 (Pt 8):2314-2328.
36. Bauer G, Trinka E. Nonconvulsive status epilepticus and coma. Epilepsia 2010; 51:177-190.
37. Hirsch LJ, LaRoche SM, Gaspard N, et al. American clinical neurophysiology society?s standardized critical care EEG terminology: 2012 version. J Clin Neurophysiol 2013; 30:1-27.
38. Hirsch LJ, Brenner RP, Drislane FW, et al. The ACNS subcommittee on research terminology for continuous EEG monitoring: proposed standardized terminology for rhythmic and periodic EEG patterns encountered in critically ill patients. J Clin Neurophysiol 2005; 22:128-135.
39. Kaplan PW. EEG criteria for nonconvulsive status epilepticus. Epilepsia 2007; 48 (Suppl 8):39-41.
40. Sutter R, Kaplan PW. Electroencephalographic criteria for nonconvulsive status epilepticus: synopsis and comprehensive survey. Epilepsia 2012; 53 (Suppl 3):1-51.
41. Beniczky S, Hirsch LJ, Kaplan PW, et al. Unified EEG terminology and criteria for nonconvulsive status epilepticus. Epilepsia 2013; 54 (Suppl 6):28-29.
42. Koutroumanidis M, Sakellariou D. Low frequency nonevolving generalized periodic epileptiform discharges and the borderland of hypoxic nonconvulsive status epilepticus in comatose patients after cardiac arrest. Epilepsy Behav 2015; 49:255-262.
43. van Putten MJ, Hofmeijer J. Generalized periodic discharges: pathophysiology and clinical considerations. Epilepsy Behav 2015; 49:228-233.
44. Punia V, Garcia CG, Hantus S. Incidence of recurrent seizures following hospital discharge in patients with LPDs (PLEDs) and nonconvulsive seizures recorded on continuous EEG in the critical care setting. Epilepsy Behav 2015; 49:250-254.
45. Brenner RP. Is it status?. Epilepsia 2002; 43 (Suppl 3):103-113.
46. Claassen J. How I treat patients with EEG patterns on the ictal-interictal continuum in the neuro ICU. Neurocrit Care 2009; 11:437-444.
47. Pohlmann-Eden B, Hoch DB, Cochius JI, Chiappa KH. Periodic lateralized epileptiform discharges: a critical review. J Clin Neurophysiol 1996; 13:519-530.
48. Trinka E, Leitinger M. Which EEG patterns in coma are nonconvulsive status epilepticus?. Epilepsy Behav 2015; 49:203-222.
49. Leitinger M, Beniczky S, Rohracher A, et al. Salzburg Consensus Criteria for non-convulsive status epilepticus: approach to clinical application. Epilepsy Behav 2015; 49:158-163.
50. Towne AR, Pellock JM, Ko D, De Lorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia 1994; 35:27-34.
51. Alldredge BK, Wall DB, Ferriero DM. Effect of prehospital treatment on the outcome of status epilepticus inchildren. Pediatr Neurol 1995; 12:213-216.
52. Silbergleit R, Lowenstein D, Durkalski V, Conwit R; NETT Investigators. Lessons from the RAMPART study: and which is the best route of administration of benzodiazepines in status epilepticus. Epilepsia 2013; 54 (Suppl 6):74-77.
53. Shah I, Deshmukh CT. Intramuscular midazolam vs. intravenous diazepam for acute seizures. Indian J Pediatr 2005; 72:667-670.
54. Brigo F, Nardone R, Tezzon F, Trinka E. Nonintravenous midazolam versus intravenous or rectal diazepam for the treatment of early status epilepticus: a systematic review with meta-Analysis. Epilepsy Behav 2015; 49:325-336.
55. Leppik IE, Patel SI. Intramuscular and rectal therapies of acute seizures. Epilepsy Behav 2015; 49:307-312.
56. Aggarwal R, Cardozo A, Homer JJ. The assessment of topical nasal drug distribution. Clin Otolaryngol Allied Sci 2004; 29:201-205.
57. Wermeling DP, Miller JL, Archer SM, et al. Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. J Clin Pharmacol 2001; 41:1225-1231.
58. Agarwal SK, Kriel RL, Brundage RC, et al. A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers. Epilepsy Res 2013; 105:362-367.
59. Ivaturi V, Kriel R, Brundage R, et al. Bioavailability of intranasal vs. rectal diazepam. Epilepsy Res 2013; 103:254-261.
60. Kälviäinen R. Intranasal therapies for acute seizures. Epilepsy Behav 2015; 49:303-306.
61. Arya R, Gulati S, Kabra M, et al. Intranasal versus intravenous lorazepam for control of acute seizures in children: a randomized open-label study. Epilepsia 2011; 52:788-793.
62. Ahmad S, Ellis JC, Kamwendo H, Molyneux E. Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open randomised trial. Lancet 2006; 367:1591-1597.
63. Lahat E, Goldman M, Barr J, et al. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study. BMJ 2000; 321:83-86.
64. Mahmoudian T, Zadeh MM. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy Behav 2004; 5:253-255.
65. Javadzadeh M, Sheibani K, Hashemieh M, Saneifard H. Intranasal midazolam compared with intravenous diazepam in patients suffering from acute seizure: a randomized clinical trial. Iran J Pediatr 2012; 22:1-8.
66. Thakker A, Shanbag P. A randomized controlled trial of intranasal-midazolam versus intravenous-Diazepam for acute childhood seizures. J Neurol 2013; 260:470-474.
67. Bhattacharyya M, Kalra V, Gulati S. Intranasal midazolam vs rectal diazepam in acute childhood seizures. Pediatr Neurol 2006; 34:355-359.
68. Fişgin T, Gurer Y, Teziç T, et al. Effects of intranasal midazolam and rectal diazepam on acute convulsions in children: prospective randomized study. J Child Neurol 2002; 17:123-126.
69. de Haan GJ, van der Geest P, Doelman G, et al. A comparison of midazolam nasal spray and diazepam rectal solution for the residential treatment of seizure exacerbations. Epilepsia 2010; 51:478-482.
70. Holsti M, Dudley N, Schunk J, et al. Intranasal midazolam vs rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy. Arch Pediatr Adolesc Med 2010; 164:747-753.
71. Brigo F, Nardone R, Tezzon F, Trinka E. A Common reference-based indirect comparison meta-Analysis of buccal versus intranasal midazolam for early status epilepticus. CNS Drugs 2015; 29:741-757.
72. Siegel RA, Kapoor M, Cheryala N, et al. Water-soluble benzodiazepine prodrug/enzyme combinations for intranasal rescue therapies. Epilepsy Behav 2015; 49:347-350.
73. Papillard S. Safety and efficacy of buccal midazolam vs rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Arch Pediatr 2005; 12:1644-1645.
74. Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012; 366:591-600.
75. Welch RD, Nicholas K, Durkalski-Mauldin VL, et al. Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric population. Epilepsia 2015; 56:254-262.
76. Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014; 55:791-802.
77. Szaflarski JP, Bebin EM. Cannabis, cannabidiol, and epilepsy: from receptors to clinical response. Epilepsy Behav 2014; 41:277-282.
78. Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. N Engl J Med 2015; 373:1048-1058.
79. Wallace MJ, Blair RE, Falenski KW, et al. The endogenous cannabinoid system regulates seizure frequency and duration in a model oftemporal lobe epilepsy. J Pharmacol Exp Ther 2003; 307:129-137.
80. Deshpande LS, Sombati S, Blair RE, et al. Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy. Neurosci Lett 2007; 411:11-16.
81. Deshpande LS, Blair RE, Ziobro JM, et al. Endocannabinoids block status epilepticus in cultured hippocampal neurons. Eur J Pharmacol 2007; 558:52-59.
82. Stell BM, Brickley SG, Tang CY, et al. Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors. Proc Natl Acad Sci USA 2003; 100:14439-14444.
83. Naylor DE, Liu H, Wasterlain CG. Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 2005; 25:7724-7733.
84. Rogawski MA, Loya CM, Reddy K, et al. Neuroactive steroids for the treatment of status epilepticus. Epilepsia 2013; 54 (Suppl 6):93-98.
85. Vaitkevicius H, Ng M, Moura L, et al. Successful allopregnanolone treatment of new onset refractory status epilepticus (NORSE) syndrome: first in man experience. Epilepsia 2013; 54 (Suppl 6):114.
86. Broomall E, Natale JE, Grimason M, et al. Pediatric super-refractory status epilepticus treated with allopregnanolone. Ann Neurol 2014; 76:911-915.
87. Iyer VN, Hoel R, Rabinstein AA. Propofol infusion syndrome in patients with refractory status epilepticus: an 11-year clinical experience. Crit Care Med 2009; 37:3024-3030.
88. Prabhakar H, Kalaivani M. Propofol versus thiopental sodium for the treatment of refractory status ticus. Cochrane Database Syst Rev 2015; 6:CD009202.
89. Rossetti AO, Milligan TA, Vulliemoz S, et al. A randomized trial for the treatment of refractory status epilepticus. Neurocritical care 2011; 14:4-10.
90. Sutter R, Kaplan PW. Can anesthetic treatment worsen outcome in status epilepticus?. Epilepsy Behav 2015; 49:294-297.
91. Sutter R, Marsch S, Fuhr P, et al. Anesthetic drugs in status epilepticus : risk or rescue?. A six-year cohort study. Neurology 2013; 82:656-664.
92. Marchi NA, Novy J, Faouzi M, et al. Status epilepticus: impact of therapeutic coma on outcome. Crit Care Med 2015; 43:1003-1009.
93. Hocker S. Systemic complications of status epilepticus: an update. Epilepsy Behav 2015; 49:83-87.
94. Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007; 13:21-42.
95. Höfler J, Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia 2013; 54:393-404.
96. Höfler J, Unterberger I, Dobesberger J, et al. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia 2011; 52:e148-E152.
97. Ramsay RE, Sabharwal V, Khan F, et al. Safety & pK of IV loading dose of lacosamide in the ICU. Epilepsy Behav 2015; 49:340-342.
98. Sutter R, Marsch S, Rüegg S. Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study. CNS Drugs 2013; 27:321-329.
99. Garcé s M, Villanueva V, Mauri JA, et al. Factors influencing response to intravenous lacosamide in emergency situations: LACO-IV study. Epilepsy Behav 2014; 36:144-152.
100. Husain AM. Lacosamide in status epilepticus: update on the TRENdS study. Epilepsy Behav 2015; 49:337-339.
101. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res 2015; 111:85-141.
102. White HS, Alex AB, Pollock A, et al. A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. Epilepsia 2012; 53:134-146.
103. Shekh-Ahmad T, Hen N, Yagen B, et al. Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-Active derivative of valproic acid with low teratogenic potential. Epilepsia 2014; 55:353-361.
104. Shekh-Ahmad T, Mawasi H, McDonough JH, et al. The potential of secbutylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. Epilepsy Behav 2015; 49:298-302.
105. Bar-Klein G, Swissa E, Kamintsky L, et al. sec-Butyl-propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats. Epilepsia 2014; 55:1953-1958.
106. NCT00140179. https://clinicaltrials.gov/ct2/show/NCT00140179?term=-valnoctamide&rank=1. [Accessed 9 November 2015]
107. Wasterlain CG, Naylor DE, Liu H, et al. Trafficking of NMDA receptors during status epilepticus: therapeutic implications. Epilepsia 2013; 54 (Suppl 6):78-80.
108. Wang J, Liu S, Haditsch U, et al. Interaction of calcineurin and type-A GABA receptor gamma 2 subunits produces long-Term depression at CA1 inhibitory synapses. J Neurosci 2003; 23:826-836.
109. Dorandeu F, Dhote F, Barbier L, et al. Treatment of status epilepticus with ketamine, are we there yet?. CNS Neurosci Ther 2013; 19:411-427.
110. Wasterlain CG, Baldwin R, Naylor DE, et al. Rational polytherapy in the treatment of acute seizures and status epilepticus. Epilepsia 2011; 52 (Suppl 8):70-71.
111. Dorandeu F, Carpentier P, Baubichon D, et al. Efficacy of the ketamineatropine combination in the delayed treatment of soman-induced status epilepticus. Brain Res 2005; 1051 (1-2):164-175.
112. Martin BS, Kapur J. A combination of ketamine and diazepam synergistically controls refractory status epilepticusinduced by cholinergic stimulation. Epilepsia 2008; 49:248-255.
113. Bankstahl JP, Löscher W. Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus. Epilepsy Res 2008; 82:70-85.
114. Brandt C, Töllner K, Klee R, et al. Effective termination of status epilepticus by rational polypharmacy in the lithium-pilocarpinemodel in rats: window of opportunity to prevent epilepsy and prediction of epilepsy by biomarkers. Neurobiol Dis 2015; 75:78-90.
115. Rossetti AO, Logroscino G, Bromfield EB. A clinical score for prognosis of status epilepticus in adults. Neurology 2006; 66:1736-1738.
116. Leitinger M, Höller Y, Kalss G, et al. Epidemiology-based mortality score in status epilepticus (EMSE). Neurocrit Care 2015; 22:273-282.
117. NCT02477618. https://clinicaltrials.gov/ct2/show/NCT02477618. [Accessed 30 December 2015]
118. Cock HR, Group E. Established status epilepticus treatment trial (ESETT). Epilepsia 2011; 52 (Suppl 8):50-52.
119. Bleck T, Cock H, Chamberlain J, et al. The established status epilepticus trial 2013. Epilepsia 2013; 54 (Suppl 6):89-92.
120. NCT01960075. https://clinicaltrials.gov/ct2/show/NCT01960075?term=Established+Status+Epilepticus+Trial&rank=1. [Accessed 30 December 2015]